InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.735 0.015 (2.08%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$351 Starpharma commences phase 1/2 DEP irinotecan trial 8 Aug 2019 9:08AM $1.230 $0.735 fallen by 40.24%
$351 Appendix 3B 29 Jul 2019 1:12PM $1.335 $0.735 fallen by 44.94%
$351 Quarterly Cashflow Report 16 Jul 2019 9:34AM $1.340 $0.735 fallen by 45.15%
$351 Shareholder Update July 2019 1 Jul 2019 9:55AM $1.360 $0.735 fallen by 45.96%
$351 VivaGel BV launched in Europe 27 Jun 2019 11:26AM $1.360 $0.735 fallen by 45.96%
$351 Starpharma presents at Macquarie Emerging Leaders Forum 20 Jun 2019 10:10AM $1.285 $0.735 fallen by 42.80%
$351 US patent granted for DEP Bcl2/xL inhibitor conjugates 12 Jun 2019 8:53AM $1.385 $0.735 fallen by 46.93%
$351 Okamoto launches VivaGel condom in Japan 4 Jun 2019 8:35AM $1.340 $0.735 fallen by 45.15%
$351 Starpharma signs second oncology agreement with AstraZeneca 3 Jun 2019 8:47AM $1.305 $0.735 fallen by 43.68%
$351 Starpharma presents at UBS Healthcare Conference 29 May 2019 9:43AM $1.280 $0.735 fallen by 42.58%
$351 DEP irinotecan combination outperforms in colon cancel model 24 May 2019 9:42AM $1.285 $0.735 fallen by 42.80%
$351 Regulatory progress for VivaGel BV in the US 23 May 2019 9:29AM $1.300 $0.735 fallen by 43.46%
$351 Starpharma to present at US Drug Delivery Conference 7 May 2019 12:06PM $1.285 $0.735 fallen by 42.80%
$351 Starpharma presents at Macquarie Australia Conference 1 May 2019 10:18AM $1.245 $0.735 fallen by 40.96%
$351 Ceasing to be a substantial holder 1 May 2019 8:15AM $1.260 $0.735 fallen by 41.67%
$351 Quarterly Cashflow Report 29 Apr 2019 11:04AM $1.260 $0.735 fallen by 41.67%
$351 First VivaGel BV launch globally in Australia by Aspen 16 Apr 2019 9:46AM $1.080 $0.735 fallen by 31.94%
$351 Starpharma meets with US FDA to discuss VivaGel BV 11 Apr 2019 9:33AM $1.070 $0.735 fallen by 31.31%
$351 Starpharma Investor Presentation to Goldman Sachs Conference 3 Apr 2019 10:24AM $0.980 $0.735 fallen by 25%
$351 Appendix 3B 19 Mar 2019 1:03PM $1.020 $0.735 fallen by 27.94%
$351 Shareholder Update March 2019 18 Mar 2019 2:19PM $1.020 $0.735 fallen by 27.94%
$351 Starpharma receives $4.0M R&D tax incentive refund 12 Mar 2019 9:26AM $1.020 $0.735 fallen by 27.94%
$351 Interim Report and Half-Yearly Financial Results 27 Feb 2019 10:27AM $1.070 $0.735 fallen by 31.31%
$351 Appendix 3B 8 Feb 2019 12:58PM $1.075 $0.735 fallen by 31.63%
$351 Quarterly Cashflow Report 30 Jan 2019 10:11AM $1.110 $0.735 fallen by 33.78%

451 - 475 of 883 results

Page 19 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.